1. 2015 MBSW1 Quality Assurance Test of Delivered Dose Uniformity of Multi-dose Spray and Inhalation Drug Products Drs. Yi Tsong 1, Xiaoyu (Cassie) Dong* 1, Meiyu Shen 1 & Richard T. Lostritto 2 1: Office of Biostatistics/Office of Translational Sciences, CDER, FDA 2: Office of Pharmaceutical Quality, CDER, FDA

2. Disclaimer This article reflects the views of the authors and should not be construed to represent FDA’s views or policies. 22015 MBSW

3. 3 Outline I.Introduction II.USP DDU Test III.Two One-Sided Tolerance Intervals (TOSTI) DDU Test IV.FDA Large Sample DDU Proposal V.Summary VI.Main References 2015 MBSW

4. I. Introduction 42015 MBSW

5. 5 Multi-dose Inhaler/Spray A multi-dose inhaler/spray (MDI) delivers a specific amount of drug in aerosol or solution form. Multi-dose nasal sprays are commonly used to treat allergy related symptoms. http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a6eaedb3-5c96-4859-be43- a48c9c818bc7&type=display 2015 MBSW Multi-dose nasal spray

6. 6 Delivered Dose Uniformity (DDU) The delivered dose measures the amount of medication delivered to the patients and should be close to the target dose as label claimed. Uniformity of the delivered dose is a critical quality attribute (in-vitro performance) to ensure the quality, efficacy and safety for of MDI products. DDU is an important requirement for batch release and quality assurance. 2015 MBSW

7. II. 601 DDU Test 72015 MBSW

8. 8 USP DDU Test The test for DDU in the FDA 1999 Draft Guidance was adopted into the 2011 in-process revision of USP. Tier 1, 10 containers (10 beginning, 10 end) If 3~6 out of 20  (80,120) Complies Yes Tier 2, additional 20 containers (20/20) At most 6 of 60  (80%,120%) None is outside (75%, 125%) Average of each 30  (85%,115%) YesNot complies Complies At most 2 of 20  (80%, 120%) None is outside (75%, 125%) Average of each 10  (85%,115%) No 2015 MBSW

9. 9 A counting method: converts a continues variable (DD) into a binary variable (outside/inside): Sampling by Variable vs. Sampling by Attribute Only applicable to the samples, not for inference on the entire batch. –No clear definition of the product quality; –Not a statistically based sampling plan. –The sample is OK ≠ The batch is OK. Zero Tolerance Outside (75%, 125%): –To detect extreme data. –It is no effect for small sample; –Not reward large samples; USP DDU Test 2015 MBSW

10. Is the USP DDU test a batch release test? 10 USP DDU Test 2015 MBSW Can the USP test make inference on the entire batch? No. Only applicable to the samples, not for inference on the entire batch. Is the USP test a stringent test for batch release? No. Whenever tested, the product needs to meet the USP acceptance criteria. Thus, a batch release test is usually more stringent than the USP test. Needs a statistically sound approach for batch release: the tolerance interval approach controls the coverage within a specific interval (say 80 – 120%LC).

11. III. Two One-sided Tolerance Intervals DDU Test 112015 MBSW

12. 12 Two One-sided Tolerance Intervals Procedure (TOSTI) In 2003, IPAC-RS (International Pharmaceutical Aerosol Consortium on Regulation and Science) proposed a two-sided tolerance interval approach as an improvement for the control of DDU of orally inhaled and nasal drug products. Coverage as the quality requirement; In 2005, FDA proposed a two one-sided tolerance intervals (TOSTI) procedure to test if the batch complies and presented this procedure to the Advisory Committee of Pharmaceutical Science, in October 2005. Coverage as the quality requirement; 2015 MBSW

13. 13 TOSTI - Product Quality Definition Two-sided TI: Most lot (>P%) within (80%, 120%) Two one-sided TIs: Not much outside each end of (80%, 120%) WITH 95% CONFIDENCE efficacy safety p1p1 p2p2 13 2015 MBSW

14. 14 Small sample n 1 =10/10/20/20, P = 87.5%, L=80, U=120: Reject H 0 if With L= 80% LC, U = 120% LC, P U = P L = 6.25% and Pocock alpha spending function, K 1 = 2.45 at the 1st tier and K 2 = 1.94 at the 2nd tier. TOSTI - Statistical Hypotheses 14 Efficacy Safety 2015 MBSW

15. Tier 1, 10 containers (10 beginning, 10 end) Complies Yes Tier 2, additional 20 containers (20 beginning, 20 end) Yes No Not complies Complies Average of each 10  (85%,115%) Average of each 30  (85%,115%) TOSTI – Test Flow Chart 2015 MBSW15

16. 16 USP TOSTI Quality Def.Not clearCoverage Mean limit85-115% of LC Zero ToleranceNone outside 75-125%Removed # of Tiers 2 tiers with a 1:3 ratio of sample sizes Tier sample size10/10/20/20 Tier II testing versus Tier-I Less likely to pass at Tier-II (individual limit effect) More likely to pass at Tier-II (design feature of the test) TOSTI vs. USP Reference: Parametric Tolerance Interval Test for Delivered Dose Uniformity (DDU) Working Group Update, Moheb M. Nasr, Ph.D., Advisory Committee of Pharmaceutical Science October 25, 2005 2015 MBSW

17. 17 Acceptance probability of two one-sided tests and USP DDU method for two-tier multiple-dose (10/10/20/20) with batch of on-target and off-target means. TOSTI vs. USP 2015 MBSW

18. 18 The requirement of the sample means between 85% and 115% almost has no impact on the acceptance probabilities for TOSTI. Acceptance probability of One-Tier (30/30) and Two-Tier (10/10/20/20) two One-sided Tolerance Interval Approach against Standard Deviation without and with requirement on means within (85,115)% Label Claim 2015 MBSW

19. IV. FDA Large Sample DDU Proposal 192015 MBSW

20. 20 FDA Large Sample DDU Proposal The manufacturer may use a sample size different from the USP specified sample size. –A larger number of canisters provide more precise estimation and more powerful test for quality assurance. –A small sample size between 10 and 30 of canisters may be more preferred if the product is less variable. We extend the proposed TOSTI procedure for a variety of sample sizes becayuse the USP-compendia small sample DDU test serves only for the evaluation of the samples instead of providing quality assurance to a batch. 2015 MBSW

21. 21 FDA Large Sample DDU Proposal It is based on TOSTI with one tier (30/30); No requirement on mean values to be within (85, 115)%LC; Basic Idea: –Pick up a Matching Point: a reference point (90% power) of a reference OC Curve (30/30 TOSTI OC Curve). –All OC curves of various sample sizes intersect at the Matching Point; –Calculate the specification for the null hypotheses (p 1, p 2 ) at α = 5%. 2015 MBSW

22. 22 FDA Large Sample DDU Proposal 2015 MBSW

23. 17 Given the power function, we develop a two-step method to determine p(n*): matching on 90% power with 30/30 OC Step 1: Solve for k subject to Step 1: Solve for k subject to Step 2: Solve for p(n) from Step 2: Solve for p(n) from FDA Large Sample DDU Proposal 2015 MBSW

24. 24 FDA Large Sample DDU Proposal n/n15/1525/2550/5060/6090/90120/120150/150200/200 γ* = 90%10.067.034.644.223.483.092.842.58 Specifications in percentage of p 0 = Pr (X 120) for one-tier TOSTI for various sample sizes n/n (n samples at beginning and n samples at end) with the matching point at γ* acceptance probability for lots with μ = 100, p 0 = 6.25% for 30/30 sample size. 2015 MBSW

25. V. Summary 252015 MBSW

26. 26 Summary TOSTI is a batch release test which controls the quality by the coverage within (80%, 120%) of the label claim; Furthermore, the TOSTI approach accepts a batch only if both portions of units being under-delivered (e.g. 120% safety concern) are controlled. It can be adjusted for a two-tier group sequential sampling acceptance plan: –Additional acceptance probability at the 2 nd tier; –More discriminating power between lots with on-target mean and off- target mean. 2015 MBSW

27. TOSTI approach can be easily illustrated as a procedure with two one-sided tests or with a two one-sided tolerance intervals concept with exact solutions. When using a single-tier sampling plan, the TOSTI procedure can also be extended to any sample size. The extension was made by protecting the acceptance rate for lots considered to be high quality in DDU. 27 Summary 2015 MBSW

28. Main References FDA Draft Guidance (1998) “FDA/CDER. Guidance for Industry “Nasal Spray and Inhalation Solution, Suspension, and Spray Drug Products--Chemistry, Manufacturing, and Controls Documentation”. Draft: May 1999”. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinform ation/guidances/ucm070575.pdf http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinform ation/guidances/ucm070575.pdf Tsong, Y., Dong, X., Shen, M., Lostritto R.T. (2015). “Quality assurance test of delivered dose uniformity of multiple-dose inhaler and dry powder inhaler drug products”. Journal of Biopharmaceutical Statistics. 25(2):328-38. Tsong Y, Shen M, Lostritto RT, Poochikian GK (2008). Parametric two-tier sequential quality assurance test of delivery dose uniformity of multiple-dose inhaler and dry powder inhaler drug products. Journal of Biopharmaceutical Statistics, 18:5, 976-984. USP General Chapter Inhalation and Nasal Drug Products: Aerosols, Sprays, and Powders—Performance Quality Tests” http://www.pharmacopeia.cn/v29240/usp29nf24s0_c601_viewall.html http://www.pharmacopeia.cn/v29240/usp29nf24s0_c601_viewall.html 2015 MBSW28

29. Main References Moheb M. Nasr. (2005) “Parametric Tolerance Interval Test for Delivered Dose Uniformity (DDU) Working Group Update”, Ph.D., Advisory Committee of Pharmaceutical Science October 25, 2005 Bo Olsson (2003), “A Parametric Tolerance Interval Test for Improved Control of Delivered Dose Uniformity of Orally Inhaled and Nasal Drug Products.” IPAC-RS Presentaion, Rockville, MD 2015 MBSW29

30. Thank you! 302015 MBSW